Azora 10-Q: $22.0M Cash, Going-Concern Doubt, Material Weakness Disclosed
Summary
Azora's first post-merger 10-Q shows $22.0 million of cash, a $118.6 million nine-month net loss and an explicit going-concern warning, alongside a newly disclosed material weakness in merger accounting controls. The November 2 Series A conversion lifted stockholders' equity back above the $2.5 million Nasdaq minimum.
Key Events · Earnings and Guidance · ADIL
-
Going-Concern Doubt on $22.0M Cash
Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year of issuance, with $22.0 million of cash and cash equivalents at September 30, 2026 against a $118.6 million nine-month net loss.
-
Material Weakness in Merger Accounting
A material weakness in internal control over financial reporting was identified during Q2 2026 preparation, related to accounting for the Merger, Financing and Azora Note Exchange; the CEO and CFO concluded disclosure controls and procedures were not effective.
-
Phase 1b Funding Not in Operating Plan
Existing cash is expected to fund IND-enabling studies and the Phase 1a study only; the Phase 1b proof-of-concept study will not start without additional funding, and Milestone Warrant purchases had raised just about $0.8 million as of November 6, 2026.
-
Series A Conversion Restores Nasdaq Equity
On November 2, 2026, 9,924.260 Series A preferred shares converted into 9,924,260 common shares, leaving 3,006.341 preferred shares outstanding under beneficial ownership limits; stockholders' equity now exceeds the $2.5 million Nasdaq continued listing requirement.
Analysis · ADIL · Life Sciences
The headline is a going-concern warning: management states plainly that substantial doubt exists about the company's ability to continue as a going concern within one year of issuance, with $22.0 million of cash against a $118.6 million nine-month net loss. Funding for the AT177 ulcerative colitis program is the crux. An IND is planned for the first half of 2027, followed by a Phase 1a study, but the operating plan does not fund the Phase 1b at all; that depends on PIPE investors voluntarily buying Milestone Warrants, of which only about $0.8 million had been purchased as of November 6, 2026. Layered on top is a newly disclosed material weakness in internal controls over the Merger, Financing and Note Exchange accounting, with disclosure controls concluded not effective. The offsetting positive is mechanical: the November 2 conversion of 9,924.260 Series A preferred shares into 9,924,260 common shares pushed stockholders' equity above the $2.5 million Nasdaq continued listing threshold, and the $80.9 million milestone warrant liability moved to equity, cleaning up the balance sheet presentation.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIL was trading at $4.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.